Metraipolis › archive › dc_7ba77fe15d0d

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals — Europe PMC PMID:34855920

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/34855920
DOI
10.1371/journal.pone.0260970
License (as archived)
CC0-1.0
Archived
2026-11-01T05:22:26.122Z
SHA-256 of the archived text
d8e5c9afc753fd86d7fbcf399b9d93f036e98118c5d5d82dfa770c54e958e73a
Stable URL of this page
https://metraipolis.com/documento/dc_7ba77fe15d0d

How to cite

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals — Europe PMC PMID:34855920 — Europe PMC (en), https://europepmc.org/article/MED/34855920 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_7ba77fe15d0d (Metraipolis archive dc_7ba77fe15d0d, sha256 d8e5c9afc753fd86d7fbcf399b9d93f036e98118c5d5d82dfa770c54e958e73a)
BibTeX
@misc{dc7ba77fe15d0d,
  title = {The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals — Europe PMC PMID:34855920},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/34855920},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_7ba77fe15d0d; sha256 d8e5c9afc753fd86d7fbcf399b9d93f036e98118c5d5d82dfa770c54e958e73a},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/34855920. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Direct-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people. We aim to evaluate the treatment outcomes of sofosbuvir- based regimens for treatment of HCV in a real life setting in Alaska Native/American Indian (AN/AI) people. Methods: AN/AI patients within the Alaska Tribal Health System with confirmed positive anti-HCV and HCV RNA, who were 18 years of age and older were included in the study. Pretreatment baseline patient characteristics, treatment efficacy based on sustained virologic response (SVR) 12 weeks after treatment completion, and adverse effects were assessed. The following treatments were given according to the American Association for the Study of Liver Diseases/Infectious Disease Society of America (AASLD/IDSA) HCV Guidance: ledipasvir/sofosbuvir, sofosbuvir plus weight-based ribavirin, and sofosbuvir/velpatasvir. Results: We included 501 patients with a mean age of 54.3 (range 21.3-78.3) in the study. Overall SVR was achieved in 95.2% of patients who received one of the three DAA regimens. For those with cirrhosis, overall SVR was 92.8% and for those with genotype 3 91.1% achieved SVR. The most common symptom experienced during treatment was headache. Joint pain was found to decrease during treatment. One person discontinued sofosbuvir plus ribavirin due to myocardial infarction and one discontinued sofosbuvir/velpatasvir due to urticaria. Conclusions: In the real-world setting, sofosbuvir-based treatment is safe, effective, and well tolerated in AN/AI patients. Sustained virologic response was high regardless of HCV genotype or cirrhosis status.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-12-02).
Identificativi: PMID 34855920 · PMCID PMC8639063 · DOI 10.1371/journal.pone.0260970.
Pagina: https://europepmc.org/article/MED/34855920 — https://doi.org/10.1371/journal.pone.0260970. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-01T05:14:20.495Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.